AP2004002994A0 - Nutrient therapy for immuno-compromised patients - Google Patents

Nutrient therapy for immuno-compromised patients

Info

Publication number
AP2004002994A0
AP2004002994A0 APAP/P/2004/002994A AP2004002994A AP2004002994A0 AP 2004002994 A0 AP2004002994 A0 AP 2004002994A0 AP 2004002994 A AP2004002994 A AP 2004002994A AP 2004002994 A0 AP2004002994 A0 AP 2004002994A0
Authority
AP
ARIPO
Prior art keywords
support
mitochondria
failure
muscle mass
sod
Prior art date
Application number
APAP/P/2004/002994A
Other languages
English (en)
Inventor
Carl Germano
Original Assignee
Millennium Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Biotechnologies Inc filed Critical Millennium Biotechnologies Inc
Publication of AP2004002994A0 publication Critical patent/AP2004002994A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
APAP/P/2004/002994A 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients AP2004002994A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/927,174 US6503506B1 (en) 2001-08-10 2001-08-10 Nutrient therapy for immuno-compromised patients
PCT/US2002/025358 WO2003013438A2 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients

Publications (1)

Publication Number Publication Date
AP2004002994A0 true AP2004002994A0 (en) 2004-03-31

Family

ID=25454328

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/002994A AP2004002994A0 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients

Country Status (9)

Country Link
US (1) US6503506B1 (https=)
EP (1) EP1432436A4 (https=)
JP (1) JP2005501061A (https=)
CN (1) CN1568196A (https=)
AP (1) AP2004002994A0 (https=)
CA (1) CA2457624A1 (https=)
EA (1) EA006439B1 (https=)
OA (1) OA12649A (https=)
WO (1) WO2003013438A2 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
FR2822704B1 (fr) * 2001-03-29 2005-02-18 Chiesi Sa Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
JP5473190B2 (ja) * 2003-10-16 2014-04-16 ネステク ソシエテ アノニム 化学療法又は放射線療法の副作用に対する栄養組成物
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
PT1711070E (pt) * 2004-01-28 2016-02-15 Nestec Sa Composição nutricional para melhorar o estado da pele e prevenir doenças de pele
US20050209170A1 (en) * 2004-03-18 2005-09-22 Takemoto Arnold C Breast health preparations
BRPI0508914A (pt) * 2004-03-17 2007-08-14 Arnold C Takemoto desintoxicação de tecidos e suplementos para a saúde e processos de obtenção e de utilização dos mesmos
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
DE602004027120D1 (de) * 2004-05-25 2010-06-24 Cognis Ip Man Gmbh Orale und/oder topische Zubereitungen
US20050265990A1 (en) * 2004-06-01 2005-12-01 Shawn Talbott Treatments and nutritional supplements for assisting post-exercise recovery
EP2177907B1 (en) * 2004-06-30 2014-01-01 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use therefor
KR100584891B1 (ko) 2004-08-13 2006-05-30 (주)씨스팜 경구용 슈퍼옥사이드 디스뮤타제 제제인, 캔털루프 멜론추출물과 글리아딘 결합물을 숙취해소에 사용하는 방법
US7284385B2 (en) * 2004-09-16 2007-10-23 Hess Spencer W Pre-dried air reactivation for diesel fuel heated dessicant reactivator
JP5040060B2 (ja) * 2004-10-14 2012-10-03 大正製薬株式会社 メチオニン配合内服液剤
US20060147550A1 (en) * 2004-12-30 2006-07-06 Gorsek Wayne F Immune system enhancement and stimulation formulation
US20070114476A1 (en) * 2005-11-04 2007-05-24 Williams Christopher P Low radiocarbon nucleotide and amino acid dietary supplements
US8329646B2 (en) * 2005-11-30 2012-12-11 Nestec S.A. Methods for the treatment of muscle loss
JPWO2007077995A1 (ja) * 2006-01-05 2009-06-11 協和発酵バイオ株式会社 筋肉増量剤
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
CA2645674A1 (en) * 2006-03-15 2007-09-20 Isocell Pharma S.A. Pharmaceutical compositions comprising sods and prolamine based peptide fragments
FR2899065B1 (fr) * 2006-03-29 2008-07-18 Alain Dreyer Brevets Et Dev So Sod micro encapsulee et adsorbee sur support mineral et vegetal destinee a l'alimentation animale
DE102006046960A1 (de) * 2006-10-04 2008-04-10 Euro Allianz Pharma Gmbh Gesundheitsfördernde Nahrungsmittelzusammensetzung
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
US8343541B2 (en) * 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
EP2158462A4 (en) 2007-05-03 2010-05-05 Radiocarb Genetics Inc FOOD SUPPLEMENTS WITH LITTLE RADIO CARBON AND MANUFACTURING METHOD THEREFOR
WO2009042230A1 (en) * 2007-09-27 2009-04-02 Biopolymer Engineering, Inc. Dba Biothera, Inc ß-GLUCAN TREATMENT OF UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING
WO2009099444A1 (en) * 2008-02-08 2009-08-13 Millennium Biotechnologies, Inc. Nutritional formula for athletes' recovery
MX2010011032A (es) 2008-04-11 2011-03-01 Cytotech Labs Llc Star Metodos y uso de induccion de apoptosis en celulas cancerigenas.
US8865733B2 (en) * 2008-11-06 2014-10-21 Altman Enterprises, LLC Medication and treatment for disease
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
EP2311449A1 (de) * 2009-10-14 2011-04-20 NÖM Aktiengesellschaft Oral verabreichbare nahrungsergänzende Zusammensetzung enthaltend Carnitin
PH12022550598A1 (en) 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
WO2012097061A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
BR112013018397A2 (pt) 2011-01-18 2016-10-11 Equine Nutriceuticals Llc suplemento equino nutricional
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN105709212A (zh) * 2016-01-29 2016-06-29 周瑞华 一种免疫平衡调节剂及其制备方法和应用
RU2656544C1 (ru) * 2017-07-07 2018-06-05 Общество с ограниченной ответственностью "Академия-Т" Функциональный продукт питания для коррекции психофизиологического состояния и нейромышечной передачи у спортсменов
CA3109188A1 (en) * 2018-08-10 2020-02-13 Maine Natural Health Company, Inc. Comestible compositions for promoting atp synthesis
CN110664824B (zh) * 2019-08-09 2021-01-01 北京佳博泰和健康科技有限公司 一种营养支持剂及其制备方法和用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
IT1258491B (it) * 1992-09-24 1996-02-26 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
FR2729296B1 (fr) 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients

Also Published As

Publication number Publication date
CN1568196A (zh) 2005-01-19
OA12649A (en) 2006-06-16
EP1432436A4 (en) 2005-02-09
EP1432436A2 (en) 2004-06-30
EA200400291A1 (ru) 2004-08-26
US6503506B1 (en) 2003-01-07
JP2005501061A (ja) 2005-01-13
WO2003013438A2 (en) 2003-02-20
CA2457624A1 (en) 2003-02-20
WO2003013438A3 (en) 2003-06-19
EA006439B1 (ru) 2005-12-29

Similar Documents

Publication Publication Date Title
AP2004002994A0 (en) Nutrient therapy for immuno-compromised patients
US6262019B1 (en) Method of treatment of glutathione deficient mammals
EP1439831B1 (en) Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
JP2005501061A5 (https=)
US20040071825A1 (en) Agglomerated granular protein-rich nutritional supplement
EP2205100B1 (en) Method for decreasing bitterness and improving taste of protein-free and hydrolyzed infant formulas
Zhan et al. The antioxidant activity of protein fractions from Sacha inchi seeds after a simulated gastrointestinal digestion
JP2009534323A5 (https=)
PT923315E (pt) Formula nutricional para pacientes com fenilcetonuria
Khan Nutritional and medical perspectives of whey protein: a historical overview
RU2008107342A (ru) Питание для пациентов, страдающих ожирением
KR20050071562A (ko) 글루타민을 제공하기 위한 방법 및 조성물
Lee et al. Plant-based antioxidant peptides: impact on oxidative stress and gut microbiota
CN104839695A (zh) 炎性肠病非全营养配方食品
Klatz The Official Anti-Aging Revolution: Stop the Clock Time is on Your Side for a Younger, Stronger, Happier You
Yavuz et al. The importance of animal proteins for human nutrition
Li et al. The anti-fatigue effect of black soybean peptide in mice
EP3984378A1 (en) Dietary supplement for sport use
Kempa et al. Effects of Six-Week Ginkgo biloba Supplementation on Aerobic Performance, Blood Pro/Antioxidant Balance, and Serum Brain-Derived Neurotrophic Factor in Physically Active Men
CN119214299A (zh) 一种肝病用特殊医学用途配方食品及其制备方法
Sadowska-Krępa et al. Effects of Six-Week Ginkgo biloba Supplementation
CN109832530A (zh) 减肥饮料
Elliott et al. We-P14: 410 Intakes of phosphorus, magnesium and calcium in relation to blood pressure: The intermap study
Chen et al. We-P14: 409 Supplementation of L-arginine improve endothelium-dependent vasodilation in hypercholesterolemia with impaired vasodilation
APPLETON Arginine and Citrulline.